Acute Coronary Syndrome as an Unusual Initial Presentation of T-Prolymphocytic Leukemia: A Case Report and Review of the Literature.


Journal

Case reports in hematology
ISSN: 2090-6560
Titre abrégé: Case Rep Hematol
Pays: United States
ID NLM: 101576456

Informations de publication

Date de publication:
2024
Historique:
received: 22 04 2024
accepted: 29 07 2024
medline: 4 9 2024
pubmed: 4 9 2024
entrez: 4 9 2024
Statut: epublish

Résumé

T-prolymphocytic leukaemia (T-PLL) is the most common mature T-cell leukaemia in Central Europe and is often manifested by rapidly increasing lymphocytosis, marked bone marrow infiltration and splenomegaly. In 10-15% of cases, the diagnosis is made by incidental findings in otherwise asymptomatic patients. Here we report a case of T-PLL that initially became symptomatic due to the presence of acute coronary syndrome (ACS). Initially, emergency coronary angiography with consecutive emergency 5-coronary artery bypass grafting (CABG) was performed. Leukocytosis was found perioperatively and T-PLL (with TCL1 rearrangement) was subsequently diagnosed. Despite known potential cardiotoxicity, the patient was treated with the anti-CD52 antibody alemtuzumab with a gradual dose increase from 3 mg to 30 mg per day. Systemic alemtuzumab therapy resulted in the complete remission of T-PLL in the bone marrow without any impairment to cardiac function. The patient was then eligible to undergo a consolidating allogeneic stem cell transplant (alloSCT). The reported case shows that T-PLL can also become initially symptomatic through an acute coronary syndrome on the basis of complex coronary heart disease. Targeted antileukaemic therapy with the monoclonal antibody alemzutumab can lead to effective systemic cytoreduction without cardiac dysfunction even in patients with severe cardiac disease, although cases of cardiotoxicity have been reported.

Identifiants

pubmed: 39228413
doi: 10.1155/2024/4303614
pmc: PMC11371457
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Pagination

4303614

Informations de copyright

Copyright © 2024 Christian R. Klein et al.

Déclaration de conflit d'intérêts

The authors declare that they have no conflicts of interest.

Auteurs

Christian R Klein (CR)

Department of Oncology, Hematology, Immune-Oncology and Rheumatology University Hospital Bonn, Bonn, Germany.
Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Bonn, Germany.

Felix Jansen (F)

Department of Internal Medicine II University Hospital Bonn University of Bonn, Venusberg-Campus 1, Bonn 53127, Germany.

Peter Brossart (P)

Department of Oncology, Hematology, Immune-Oncology and Rheumatology University Hospital Bonn, Bonn, Germany.
Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Bonn, Germany.

Marco Herling (M)

Department of Hematology, Cellular Therapy, and Hemostaseology University of Leipzig, Leipzig, Germany.

Georg Feldmann (G)

Department of Oncology, Hematology, Immune-Oncology and Rheumatology University Hospital Bonn, Bonn, Germany.
Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Bonn, Germany.

Classifications MeSH